Bioatla Inc BCAB.OQ BCAB.O is expected to show no change in quarterly revenue when it reports results on May 6 for the period ending March 31 2025
LSEG's mean analyst estimate for Bioatla Inc is for a loss of 35 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Bioatla Inc is $10.00, above its last closing price of $0.50.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.38
-0.30
Beat
21.1
Sep. 30 2024
-0.36
-0.36
-0.22
Beat
38.9
Jun. 30 2024
-0.47
-0.44
-0.44
Met
-0.5
Mar. 31 2024
-0.54
-0.54
-0.48
Beat
11.4
Dec. 31 2023
-0.88
-0.79
-0.56
Beat
29.3
Sep. 30 2023
-0.82
-0.80
-0.70
Beat
12.5
Jun. 30 2023
-0.63
-0.64
-0.75
Missed
-17.2
Mar. 31 2023
-0.63
-0.63
-0.58
Beat
7.6
This summary was machine generated May 2 at 21:11 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)